H-Phg(4-OH)-OH
(Synonyms: L-(+)-对羟基苯甘氨酸,L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842) 目录号 : GC38272
A CPT1 inhibitor and prodrug form of 4-hydroxyphenylglyoxylic acid
Cas No.:32462-30-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Oxfenicine is an inhibitor of carnitine palmitoyltransferase 1 (CPT1) and a prodrug form of 4-hydroxyphenylglyoxylic acid.1,2 Oxfenicine is transaminated to 4-hydroxyphenylglyoxylic acid by branched-chain amino acid aminotransferase in rat heart homogenates.3 It inhibits fatty acid oxidation and increases carbohydrate oxidation in isolated rat hearts perfused with palmitate , glucose, and insulin.4 Oxfenicine increases the ex vivo activity of cardiac pyruvate dehydrogenase (PDH) in rats with an ED50 value of 0.3 mmol/kg.1 It reduces increases in plasma levels of lactate and lactate dehydrogenase 1 (LDH-1), markers of ischemic injury, in a dog model of microsphere-induced coronary ischemia when administered at a dose of 0.1 mmol/kg.5
1.Barnish, I.T., Cross, P.E., Danilewicz, J.C., et al.Promotion of carbohydrate oxidation in the heart by some phenylglyoxylic acidsJ. Med. Chem.24(4)399-404(1981) 2.Bielefeld, D.R., Vary, T.C., and Neely, J.R.Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscleJ. Mol. Cell. Cardiol.17(6)619-625(1985) 3.Higgins, A.J., Morville, M., Burges, R.A., et al.Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heartLife Sci.27(11)963-970(1980) 4.Burges, R.A., Gardiner, D.G., and Higgins, A.J.Protection of the ischaemic dog heart by oxfenicineLife Sci.29(18)1847-1853(1981)
| Cas No. | 32462-30-9 | SDF | |
| 别名 | L-(+)-对羟基苯甘氨酸,L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842 | ||
| Canonical SMILES | O=C(O)[C@@H](N)C1=CC=C(O)C=C1 | ||
| 分子式 | C8H9NO3 | 分子量 | 167.16 |
| 溶解度 | H2O : 4.55 mg/mL (27.22 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。